Aneta Affek, Maria Niemyjska, Martyna Wełpa


1.   Stańczak J., Podstawowe informacje o rozwoju demograficznym Polski do 2014 roku, www.stat.gov.pl.

2.   Mills A. D., Nazer M. Z., Haddadin M. J., Kurth M. J., N,N-Bond-Forming Heterocyclization: Synthesis of 3-Alkoxy-2H-indazoles, J. Org. Chem, 2006, 71, 2687-2689.

3.   Elliott E. L., Bushell S. M., Cavero M., Tolan B., Kelly T. R., Total Synthesis of Nigellicine and Nigeglanine Hydrobromide, Org. Lett. 2005, 7 (12), 2449-2451.

4.   Gaikwad D. D., Chapolikar A. D., Devkate C. G., Warad K. D., Tayade A. P., Pawar R. P., Domb A. J., Synthesis of indazole motifs and their medicinal importance: An overview, Eur. J. Med. Chem., 2015, 90, 701-731.

5.   Fischer E., Seuffert O., Ueber das Indazol, Eur. J. Inorg. Chem., 1901, 34 (1), 795-798.

6.   Minkin Y. I., Garnovskii A. D., Elguero J., Katritzky A. R., Denisko O. V., The Tautomerism of Heterocycles, Five-Membered Rings with Two ot More Heteroatoms, Adv. Heterocycl. Chem., 2000, 76, 157-323.

7.   Schmidt A., Beutler A., Snovydovych B., Recent Advances in the Chemistry of indazoles, Eur. J. Org. Chem., 2008, 4073-4095.

8.   Rahman A., Malik S., Cun-heng H., Clardy J., Isolation and structure determination of nigellicyne, a novel alkaloid from the seeds of nigella sativa, Tetrahedron Lett., 1985, 26, 2759-2762.

9.   Liu Y.-M., Yang J.-S., Liu Q.-H., New Alkaloid and Its Artificial Derivative with an Indazole Ring from Nigella glandulifera, Chem. Pharm. Bull., 2004, 52, 454-455.

10.  Rahman A., Malik S., Hasan S. S., Choudhary M. I., Ni C.-Z., Clardy J., Nigellidine - a new indazole alkaloid from the seeds of nigella sativa, Tetrahedron Lett., 1995, 36, 1993-1996.

11.  Abu-Irmaileh B. E., Afifi F. U., Herbal medicine in Jordan with special emphasis on commonly used herbs, J. Etnopharmacol., 2003, 89, 193-197.

12.  Said O., Khali K., Folder S., Azaizeh H., Ethnopharmacological survey of medicinal herbs in Israel, the Golan Heights and the West Bank region, J. Ethnopharmacol., 2002, 83, 251-265.

13.  Eddouks N., Maghrani M., Lemhadri A., Quahidi M. L., Jouad H., Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet), J. Ethnopharmacol., 82, 2002, 97-103.

14.  Elliott E. L., Bushell S. M., Cavero M., Tolan B., Kelly T. R., Total Synthesis of Nigellicine and Nigeglanine Hydrobromide, Org. Lett. 2005, 7 (12), 2449-2451.

15.  Inamoto K., Katsuno M., Yoshino T., Arai Y., Hiroya K., Sakamoto T., Synthesis of 3-substituted indazoles and benzoisoxazoles via Pd-catalyzed cyclization reactions, applications to the synthesis of nigellicyne, Tetrahedron 2007, 63, 2695-2711.

16.  Thangadurai A., Minu M., Wakode S., Agrawal S., Narasimhan B., Indazole: a medicinally important heterocyclic moiety, Med. Chem. Res. 2012, 21, 1509-1523.

17.  Albert D. H., Tapang P., Magoc T. J., Pease L. J., Reuter D. R., Wei R. Q., Li J., Guo J., Bousquet P. F., Ghoreishi-Haack N. S., Wang B., Bukofzer G. T., Wang Y. C., Stavropoulos J. A., Hartandi K., Niquette A. L., Soni N., Johnson E. F., McCall J. O., Bouska J. J., Luo Y., Donawho C. K., Dai Y., Marcotte P. A., Glaser K. B., Michaelides M. R., Davidsen S. K., Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor, Mol. Cancer Ther. 2006, 5, 995-1006.

18.  Luo Y., Jiang F., Cole T. B., Hradil V. P., Reuter D., Chakravartty A., Albert D. F., Davidsen S. K., Cox B. F., McKeegan E. M., Fox G. B., A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model, Cancer Chemother. Pharmacol. 2012, 69, 911-921.

19.  Wilhelm S. M, Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L, Lynch M., Auclair D., Taylor I. Gedrich R. Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A., BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases ivolved in tumor progression and angiogenesis, Cancer Res. 2004, 64, 7099-7109.

20.  Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R. A., Schwartz B., Simantov R., Kelley S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat. Rev. Drug Discov. 2006; 5, 835-844.

21.  Chu J.-H., Zhao C.-R., Song Z.-Y., Wang R.-Q., Qin Y.-Z., Wen-Bao Li W.-B., , Xian-Jun Quo X.-J., 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib, Biomed. Pharmacother. 2014, 68, 335-341.

22.  Zhao C., Wang R., Li G. Xue X., Sun C., Qu X., Li W., Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines, Bioorg. Med. Chem. Lett. 2013, 23, 1989-1992.

23.  Lu Y.-Y., Wang J.-J., Zhang X.-K., Li W.-B., Guo X.-L., 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases, Journal of Pharmacy and Pharmacology, 2015, 67, 1393-1405.

24.   Shan Y., Dong J., Pan X., Zhang L. Zhang J., Dong Y., Wang M., Expanding the structural diversity of Bcr-Abl inhibitors, dibenzoylpiperazin incorporated with 1H-indazol-3-amine, Eur. J. Med. Chem. 2015, 104, 139-147.

25.   Lee J., Kim J., Hong V. S., Park J.-W., Synthesis and anti-proliferative activity evaluation of N3-acyl-N5-aryl-3,5-diaminoindazole analogues as anti-head and neck cancer agents, DARU J. Pharm. Sci. 2014, 22, 4-12.

26.   Song P., Chen M., Ma X., Xu L., Tao T., Yubo Zhou Y., Hu Y., Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold, Bioorg. Med. Chem. 2015, 23, 1858-1868.

27.   Abbassi N., Geffken D., Aiello C., Gangemi R. Rosano C., Viale M., Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents, Eur. J. Med. Chem. 2012, 57, 240-249.

28.   Abbassi N., Rakib El M., Chicha H., Bouissane L., Hannioui A., Aiello C., Gangemi R., Castagnola P., Rosano C., Viale M., Synthesis and antitumor activity of some substituted indazole derivatives, Arch. Pharm. Chem. Life Sci., 2014, 347, 423-431.

29.   Borst D. L., Arruda L. S., MacLean E., Pithavala Y. K., James E. Morgado J. E., Common questions regarding clinical use of axitinib in advanced renal cell carcinoma, Am. J. Health-Syst. Pharm. 2014, 71, 1092-1096.

30.   Chen Y., Tortorici M. A., Garrett M., Hee B., Klamerus K. J., Pithavala Y. K., Clinical pharmacology of Axitinib, Clin. Pharmacokinet. 2013, 52, 713-725.

31.   Pemovska T., Johnson E., Kontro M., Rapasky G. A., Chen J., Wells P., Cronin C. N., McTigue M., Kallioniemi O., Porkka K., Murray B. W., Wennerberg K., Axitinib effectively inhibits BCR-ABL1 (T316l) with a distinct binding conformation, Nature 2015, 519, 102-115.

32.   Floridi A., Paggi M. G., Marcante M. L., Silvestrini B., Caputo A., De Martino C. J. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cell, Natl. Cancer. Inst. 1981, 66, 497-499.

33.   Pelicano H., Martin D. S., Xu R.-H., Huang P., Glycolysis inhibition for anticancer treatment, Oncogene 2006, 25, 4633-4646.

34.   Di Cosimo S., Ferretti G., Papaldo P., Carlini P., Fabi A., Cognetti F., Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors, Drugs Today Barc. 2003, 39, 157-174.

35.   De Lena M., Lorusso V., Latorre A., Fanizza G., Gargano G., Caporusso L., Guida M., Catino A., Crucitta E., Sambiasi D., Mazzei A., Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study, Eur. J. Cancer 2001, 37, 364-368.

36.   Laufer R., Forrest B., Li S.-W., Liu Y., Sampson P., Edwards L., Lang Y., Awrey D. E., Mao G., Plotnikova O., Leung G., Hodgson R., Beletskaya I., Mason J. M., Luo X., Xin Wei, Yao Y., Feher M., Ban F., Reza Kiarash R., Green E., Mak T. W., Pan G., Pauls H. W, The discovery of PLK4 inhibitors: (E) 3-((1H-indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents, J. Med. Chem. 2013, 56, 6069-6087.

37.   Sampson P. B., Liu Y., Patel N. K., Feher M., Forrest B., Li S.-W., Edwards L., Laufer R., Lang Y., Ban F., Awrey D. E., Mao G., Plotnikova O., Leung G., Hodgson R., Mason J., Wei X., Kiarash R., Green E., Qiu W., Chirgadze N. Y., Mak T. W., Pan G., Pauls H. W., The discovery of polo-like kinase 4 inhibitors, design and optimization of spiro[cyclopropane-1,3’[3H]indol]-2’(1’H)-ones as orally bioavailable antitumor agents, J. Med. Chem. 2015, 58, 130-146.

38.   Sampson P. B, Liu Y., Forrest B., Cumming G., Li S.-W., Patel N. K., Edwards L., Laufer R., Feher M., Ban F., Awrey D. E., Mao G., Plotnikova O., Hodgson R, Beletskaya I., Mason J. M., Luo X., Nadeem V., Wei X., Kiarash R., Madeira B., Huang P., Mak T. W., Pan G., Pauls H. W., The discovery of polo-like kinase 4 inhibitors: identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5’-methoxyspiro[cyclopropane-1,3’-indolin]-2’-one (CFI-400945) as a potent orally active antitumor agent, J. Med. Chem. 2015, 58, 147-169.

39.   Li S.-W., Liu Y., Sampson P. B. Patel N. K., Forrest B. T., Edwards L., Laufer R., Feher M., Ban F., Awrey D. E., Hodgson R., Beletskaya I., Mao G., Mason J. M., Wei X., Luo X., Kiarash R., Green E., Mak T. W., Pan G., Pauls H. W., Design and optimization of (3-aryl-1H-indazol-6-yl)spiro [cyclopropane-1,30 -indolin]-2’ -ones as potent PLK4 inhibitors with oral antitumor efficacy, Bioorg. Med. Chem. Lett. 2016, 26, 4625-4630.

40.   Ye L., Ou X., Tian Y., Yu B., Luo Y., Feng B., Lin H., Zhang J., Wu S., Eur. Indazoles as potential c-met inhibitors: design, synthesis and molecular docking studies, J. Med. Chem. 2013, 65 112-118.

41.   Lai A., Mehmet M., Govek S., Nagasawa J., Bonnefous C., Julien J., Douglas K., Sensintaffar J., Lu N., Lee K., Aparicio A., Kaufman J., Qian J., Shao G., Prudente R., Moon M. J., Joseph J. D., Darimont B., Brigham D., Grillot K., Heyman R., Rix P. J., Hager J. H., Smith N. D., Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts, J. Med. Chem. 2015, 58, 4888-4904.

42.  Govek S.P, Nagasawa J. Y., Douglas K. L., Lai A. G., Kahraman M., Bonnefous C., Aparicio A. M., Darimont B. D., Grillot K. L., Joseph J. D., Kaufman J. A., Lee K.-J., Lu N., Moon M. J., Prudente R. Y., Sensintaffar J., Rix P. J., Hager J. H., Smith N. D., Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xerograft, Bioorg. Med. Chem. Lett. 2015, 25, 5163-5167.